

Cancer Epidemiology, Biomarkers & Prevention



Consumption of the Putative Chemopreventive Agent Curcumin by Cancer Patients: Assessment of Curcumin Levels in the Colorectum and their Pharmacodynamic Consequences

Giuseppe Garcea, David P. Berry, Donald J.L. Jones, et al.

Cancer Epidemiol Biomarkers Prev 2005;14:120-125. Published online January 24, 2005.

Updated Version Access the most recent version of this article at:
<http://cebp.aacrjournals.org/content/14/1/120>

Cited Articles This article cites 28 articles, 13 of which you can access for free at:
<http://cebp.aacrjournals.org/content/14/1/120.full.html#ref-list-1>

Citing Articles This article has been cited by 14 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/14/1/120.full.html#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.

Consumption of the Putative Chemopreventive Agent Curcumin by Cancer Patients: Assessment of Curcumin Levels in the Colorectum and their Pharmacodynamic Consequences

Giuseppe Garcea,¹ David P. Berry,² Donald J.L. Jones,¹ Raj Singh,¹ Ashley R. Dennison,² Peter B. Farmer,¹ Ricky A. Sharma,¹ William P. Steward,¹ and Andreas J. Gescher¹

¹Cancer Biomarkers and Prevention Group, Departments of Oncology and Biochemistry, University of Leicester and ²Department of Hepatobiliary Surgery, University Hospitals of Leicester, Leicester General Hospital, Leicester, United Kingdom

Abstract

Curcumin, a constituent of the spice turmeric, has been shown to reduce the adenoma burden in rodent models of colorectal cancer accompanied by a reduction of levels of the oxidative DNA adduct 3-(2-deoxy-β-di-erythro-pentafuranosyl)-pyr[1,2-α]-purin-10(3H)one (M₁G) and of expression of the enzyme cyclooxygenase-2 (COX-2). We tested the hypothesis that pharmacologically active levels of curcumin can be achieved in the colorectum of humans as measured by effects on levels of M₁G and COX-2 protein. Patients with colorectal cancer ingested curcumin capsules (3,600, 1,800, or 450 mg daily) for 7 days. Biopsy samples of normal and malignant colorectal tissue, respectively, were obtained at diagnosis and at 6 to 7 hours after the last dose of curcumin. Blood was taken 1 hour after the last dose of curcumin. Curcumin and its metabolites were detected and quantitated by high-performance liquid chromatography with detection by UV spectrophotometry or mass spectrometry. M₁G levels and COX-2 protein expression were

measured by immunoslot blot and Western blotting, respectively. The concentrations of curcumin in normal and malignant colorectal tissue of patients receiving 3,600 mg of curcumin were 12.7 ± 5.7 and 7.7 ± 1.8 nmol/g, respectively. Curcumin sulfate and curcumin glucuronide were identified in the tissue of these patients. Trace levels of curcumin were found in the peripheral circulation. M₁G levels were 2.5-fold higher in malignant tissue as compared with normal tissue ($P < 0.05$ by ANOVA). Administration of curcumin (3,600 mg) decreased M₁G levels from 4.8 ± 2.9 adducts per 107 nucleotides in malignant colorectal tissue to 2.0 ± 1.8 adducts per 107 nucleotides ($P < 0.05$ by ANOVA). COX-2 protein levels in malignant colorectal tissue were not affected by curcumin. The results suggest that a daily dose of 3.6 g curcumin achieves pharmacologically efficacious levels in the colorectum with negligible distribution of curcumin outside the gut. (Cancer Epidemiol Biomarkers Prev 2005;14(1):120–5)

Introduction

A shortcoming of the clinical development of many cancer chemopreventive agents has been the lack of knowledge, before the design of long-term phase II intervention trials, of the relationship between markers of pharmacologic activity and levels of agent required for efficacy. For example, the absence of robust pharmacokinetic information for β-carotene at the trial design stage has been implicated as one potential reason for the disappointing outcome of two large lung cancer prevention trials involving this dietary constituent (1). Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione] is a potent antioxidant derived from the spice turmeric. It exerts cancer chemopreventive efficacy in a wide variety of rodent models of carcinogenesis (2). In common with several other diet-derived polyphenols, curcumin possesses low systemic bioavailability (3). This pharmacokinetic feature of curcumin, which has been observed across several species, is the corollary of poor absorption and avid metabolic conjugation and reduction (3, 4). Poor systemic availability mitigates against using curcumin in the prevention of malignancies distant from the gastrointestinal tract. In contrast, the low systemic bioavailability of curcumin would not curtail its development in the prevention of gastrointes-

tinal malignancies, as curcumin distribution in the target tissue is, to a great extent, independent of systemic availability. Consistent with this notion oral curcumin has been shown to prevent malignancy in azoxymethane-induced colonic cancer model in rats (5) and to reduce adenoma burden in the *Apc*^{Min+} murine model of inherited colorectal cancer (6, 7). *Apc*^{Min+} mice are characterized by a mutation in the *Apc* gene mimicking the molecular defect underlying familial adenomatous polyposis in humans. The *Apc*^{Min+} model was used in the preclinical development of the cyclooxygenase-2 (COX-2) inhibitor celecoxib (8) and accurately predicted polyp-retarding activity in familial adenomatous polyposis patients (9). The mechanisms by which curcumin is thought to exert its chemopreventive efficacy include antioxidant, as reflected by a decrease in the level of the oxidative DNA adduct 3-(2-deoxy-β-di-erythro-pentafuranosyl)-pyr[1,2-α]-purin-10(3H)one (M₁G; ref. 10) and by down-regulation of the enzyme COX-2 (11, 12). Expression of COX-2 mRNA and protein is increased in human colorectal adenomas and adenocarcinomas (13–15) compared with normal tissue, intimating the possibility of COX-2 inhibition as a strategy to intercept the development of colorectal cancer. Among other pharmacologic changes elicited by curcumin which have been considered to contribute to its chemopreventive efficacy are induction of apoptosis (16, 17) and antiangiogenesis (18). The concentrations of curcumin required to elicit biochemical changes germane to chemoprevention in experiments *in vitro* are in the 5 to 50 μmol/L range. Hence, for the development of curcumin as a potential colorectal cancer chemopreventive agent, it is of paramount importance to establish whether intestinal levels of curcumin in this concentration range are

Grant support: UK Medical Research Council programme grant 1995, Association of International Cancer Research project grant 1998, and University Hospitals of Leicester Trust 2000. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Giuseppe Garcea, Department of Oncology, RKCSB, LRI, University of Leicester, Leicester, LE2 7LX, United Kingdom. Phone: 116-223-1856; Fax: 116-223-1855. E-mail: gg43@le.ac.uk

Copyright © 2005 American Association for Cancer Research.

achievable in humans who receive oral curcumin, thus potentially eliciting pharmacologic changes which, when maintained over prolonged periods of time, might elicit chemoprevention. To test this hypothesis, patients with confirmed colorectal cancer received oral curcumin at 450, 1,800, or 3,600 mg per diem for 1 week before surgery, and levels of agent-derived species were determined in the peripheral circulation and in colorectal tissue obtained at resection surgery. We also explored whether metabolites of curcumin occur in the human colorectum. Furthermore, the hypothesis was tested such that oral consumption of curcumin precipitates changes in COX-2 levels and in redox status, as reflected by M₁G adduct levels, in the colorectal mucosa. Levels of COX-2 protein and M₁G adduct in tissue obtained at resection following 1 week of curcumin administration were compared with those in biopsy samples taken at diagnosis before administration of curcumin.

Materials and Methods

Patients and Tissue Collection. Twelve patients (5 female, 7 male, ages 47-72) with confirmed colorectal carcinoma of stages Dukes A (two patients), B (three patients), or C (seven patients) were recruited into the trial following approval by the local ethics committee. All patients gave written informed consent for the use of their tissues for the designated research project. Hematologic profiles, urinary levels of urea and electrolytes, and hepatic function were within the reference range defined by the laboratories of the University Hospitals of Leicester. None of the patients had preoperative radiotherapy or chemotherapy. Their drug history included antihypertensives (four patients), diuretics (five patients), and analgesics (five patients). None of the patients were on nonsteroidal anti-inflammatory drugs at the time of curcumin administration. Tumor location was the ascending/transverse colon (three patients), sigmoid colon (six patients), and rectum (three patients).

Colorectal tissue biopsy specimens taken at diagnosis weighed 6 to 40 mg (tumor biopsies) and 8 to 30 mg (normal tissue biopsies). The weight of the surgical tissue samples for pharmacodynamic analysis was 45 to 85 mg, that of samples for chemical analysis was 1.1 to 1.5 g. Tissues were placed in liquid nitrogen immediately after collection and kept at -80°C until analysis protected from light, and storage did not exceed 1 week. Previous work (4) established that curcumin is stable under these conditions in tissues.

Curcumin Formulation and Dose. Patients (four per dose level) received a standardized turmeric extract formulated in capsules ("Curcumin C3 complex," Sabinsa Co., Piscataway, NJ). The capsule content of curcumin was confirmed by high-performance liquid chromatography (HPLC). Each capsule contained 450 mg of curcumin, 30 mg of desmethoxycurcumin, and 20 mg of bisdesmethoxycurcumin. Dose levels were 1, 4, or 8 capsules per day, translating into 450, 1,800, or 3,600 mg of curcumin daily, for 7 days before surgery. Samples of peripheral blood were taken 1 hour post dose, and colectomy was done 6 to 7 hours after the last dose of curcumin.

Analysis of Curcumin and Curcumin Conjugates. Samples of tissues and plasma were extracted and analyzed by HPLC for curcumin and its major metabolites curcumin sulfate, curcumin glucuronide, hexahydrocurcumin, and hexahydrocurcuminol, as described by previously (3, 4). Recovery of curcumin was $81 \pm 2\%$ from plasma and $76 \pm 3\%$ and $75 \pm 6\%$ from colorectal tumor tissue and normal colorectal mucosa, respectively. Authentic curcumin glucuronide and curcumin sulfate were generated by incubation of curcumin with rat liver microsomes and cytosol, respectively, with appropriate cofactors (4). Authentic hexahydrocurcumin and hexahydrocurcuminol were generated by reduction of

curcumin with sodium borohydride (3). Identification was done by HPLC cochromatography with standard materials and by mass spectrometry using a Quattro Ultima Platinum Mass Spectrometer (Micromass, Manchester, United Kingdom). For mass spectral analysis, samples (10 μL) of eluate obtained from the HPLC column containing suspected curcumin-derived species were dried and solubilized in acetonitrile/water (7:3) and injected into the mass spectrometer using a back flow of 70:30 acetonitrile/water at 50 $\mu\text{L}/\text{min}$ (Waters Alliance 2695 HPLC pump) using desolvation and source temperatures of 200°C and 120°C , respectively. The mass spectrometer was tuned up to each authentic agent before sample analysis. Analysis involved a scan of 40 to 600 m/z . Tandem mass spectrometry was used to fragment molecular ions into product ions; argon was the collision gas.

Analyses of COX-2 Protein and M₁G Adducts. COX-2 protein in colorectal tissue was determined by Western blotting using an anti-COX-2 polyclonal antibody (Santa Cruz, TX) with enhanced chemiluminescence detection as described previously (19). Protein loading was 400 μg per lane. DNA was extracted from tissue and M₁G adduct levels were measured by immunoslot blot, using monoclonal anti-M₁G antibody provided by Prof. Lawrence Marnett (Vanderbilt University, TN) as described previously (20).

Results

Identification of Curcumin and its Metabolites in Blood and Colorectal Tissue. Samples of extracts of plasma obtained from the peripheral circulation or of normal or malignant colorectal tissue were subjected to HPLC analysis. Plasma from one of the patients on the highest dose of curcumin (3,600 mg) afforded a peak coeluting with authentic curcumin (Fig. 1). This peak was not found in plasma from the other patients at this or the two lower dose levels. An abundant peak with the retention time of 38 minutes, coeluting with curcumin, was found in extracts of normal and malignant colorectal tissue in patients at all three dose levels (see, e.g., in Fig. 2). Confirmation of identity of this species as curcumin was achieved by cochromatography with authentic material of an extract of the eluate containing the peak constituent, and by mass spectrometric analysis. Mass spectra of the eluate of tissue extracts containing this peak were characterized by a predominant molecular ion at m/z 367 and a diagnostic on source collision induced a dissociation fragment at m/z of 325, consistent with the spectrum of authentic curcumin. Curcumin levels in the plasma were above the limit of detection (~ 0.3 nmol/L), but below the limit of quantitation (3 nmol/L). Levels of curcumin in normal and malignant colorectal tissue ranged from 7 to 20 nmol/g tissue (Table 1). Normal mucosa from the caecum and ascending colon contained more curcumin than normal mucosa from the transverse, splenic flexure, and descending colon. In patients who had received 1,800 or 3,600 mg of curcumin, the concentration of curcumin measured was 21.7 ± 8.2 and 6.8 ± 3.7 nmol/g in the right and left colon, respectively (mean \pm SD, $n = 4$ patients per dose level). This difference was not reflected by curcumin levels in tumor tissue originating from differential sites of the bowel. Curcumin metabolites were not detected in the plasma. Extracts of colorectal mucosa of seven of the eight patients who received 1,800 or 3,600 mg curcumin yielded an HPLC peak which coeluted with curcumin sulfate, and tissue extracts from two patients on the highest dose exhibited a peak coeluting with curcumin glucuronide (Fig. 2). Unambiguous identification of these species was achieved by mass spectrometry which afforded the molecular ions of $m/z = 543$ and 447 which when subjected to tandem mass spectrometry gave product ion spectra consistent with mass spectra for authentic curcumin glucuronide and curcumin sulfate. Curcumin




Figure 1. HPLC analyses of extract of (A) peripheral blood from a patient who had received 3,600 mg of curcumin, (B) an eluate of the peak suspected to be curcumin, (Bii) authentic curcumin at a concentration close to its detection limit (0.3 nmol/L), and (Biii) a mixture of i and ii. Arrow, retention time of curcumin. Detection was by UV spectrophotometry at 420 nm. mAU, milliabsorbance units. For details of surgery, sample preparation, and HPLC analysis, see Materials and Methods.

conjugates possess absorbance coefficients similar to those of curcumin (3), and semiquantitative interpretation of the HPLC traces suggested that the conjugates were present at concentrations near 1 pmol/g tissue. Presence of curcumin conjugates in the intestinal mucosa is consistent with the finding that curcumin undergoes avid glucuronidation and sulfation in suspensions of microsomes and cytosol, respectively, from the intestine of humans and rodents (4). Curcumin also undergoes metabolic reduction to hexahydrocurcumin and hexahydrocurcuminol (3). These metabolites were undetectable in extracts of intestinal tissue.

Effect of Curcumin on Colorectal COX-2 and M₁G Levels.

The potential pharmacodynamic activity of orally ingested curcumin in the colorectum of cancer patients was tested by assessment of its effect on the expression of COX-2 protein and on levels of M₁G. COX-2 and M₁G levels in surgical colorectal tissue samples were compared with levels in biopsy specimens obtained at the time of diagnosis. COX-2 was undetectable in normal colorectal tissue, but present in malignant colorectal tissue (Fig. 3), consistent with previous studies (21–23). Curcumin did not seem to reduce COX-2 expression in malignant colorectal tissue.

M₁G adduct levels in normal and malignant colorectal tissue were 2.3 ± 1.1 and 4.8 ± 4.9 per 10^7 nucleotides ($n = 15$, $P < 0.05$ by ANOVA), respectively, thus 2.5-fold higher in malignant tissue compared with normal tissue. Whereas administration of curcumin did not affect M₁G levels in normal colorectal mucosa, it caused a decrease in adduct levels in malignant colorectal tissue (Fig. 4). In the case of the highest curcumin dose, the difference between samples obtained pretreatment and post-treatment reached borderline significance ($P < 0.05$). To explore the relevance of the observed difference further, we investigated whether M₁G levels were affected by the specific manner in which tissue samples were obtained. Pretreatment


biopsy samples consisted predominately of malignant tissue obtained from the surface of the tumor. In contrast, samples obtained at surgery consisted of a “wedge” of tissue including tumor core. It was deemed conceivable that samples taken from the edge or the middle of the tumor could differ in M₁G levels because of differences in exposure of tissue to oxidants in the fecal stream or of variation in blood supply. To test this hypothesis, M₁G adduct levels were measured in three patients who had not received curcumin. M₁G levels in preoperative biopsy specimens were 4-fold higher than those obtained from surgically obtained tumor core, and M₁G levels in postoperative tumor edge were approximately twice as high as in tumor core obtained postsurgery (data not shown). Thus, it would seem that differences in origin of tumor sample between preoperative (and hence pretreatment) and postoperative (post-treatment) specimens could, at least in part, explain differences in M₁G levels, which might in turn obfuscate any effect of curcumin. It is important to note that the effect of curcumin on colorectal M₁G levels was borderline significant ($P < 0.05$) only in patients who had received the highest dose. If the variability in M₁G levels between pretreatment and

Table 1. Curcumin levels in normal and malignant colorectal tissue of patients who received oral curcumin daily for a week before surgery

Dose (mg)	Tissue concentration (nmol/g)	
	Tumor tissue	Normal mucosa
3,600	$7.7 \pm 1.8^*$	12.7 ± 5.7
1,800	6.7 ± 1.6	19.6 ± 14.8
450	0.9 ± 0.4	0

*Values are the mean \pm SD ($n = 4$).

Figure 2. HPLC analyses of an extract of (A) nonmalignant colonic mucosa of a patient who received curcumin 3.6 g daily for a week, (Bi) an extract of HPLC solvent eluting with the peak with retention time 25 minutes in A (solid arrow), (Bii) a solution of authentic curcumin glucuronide, and (Biii) a mixture of i and ii, (Ci) an extract of HPLC solvent eluting with the peak with retention time 31 minutes in A (broken arrow), (Cii) a solution of authentic curcumin sulfate, and (Ciii) a mixture of i and ii. The large peak at retention time 38 minutes coelutes with parent curcumin (solid triangle). Detection was by UV spectrophotometry at 420 nm. *mAU*, milliabsorbance units. Surgery was conducted 6 hours after the last of seven daily doses of curcumin. For details of surgery, sample preparation, and HPLC analysis, see Materials and Methods.



post-treatment samples were predominantly due to the spatial diversity in sample source, one would expect the pretreatment and post-treatment difference in M_1G levels to be of a similar order of magnitude in all three dose groups. Yet a marked discrepancy in pretreatment and post-treatment M_1G levels was not seen for the 450 and 1,800 mg dose groups. Thus, it seems reasonable to draw the tentative conclusions that curcumin consumption did indeed cause a decrease in M_1G levels in colorectal malignant tissue and that differences in M_1G levels related to sampling technique were unlikely to confound the effect of curcumin. With a larger sample size, the dose of 1.8 g might actually have achieved a statistically significant reduction of M_1G levels. Thus, although this study did not establish the minimal dose which decreased M_1G levels (i.e., "minimal effective dose"), we tentatively surmise that the minimal effective dose level might be >0.45 g and perhaps near 1.8 g.

Discussion

The results outlined above suggest that levels of curcumin achieved in humans after regular oral intake of 3,600 mg of curcumin furnish drug levels in the gastrointestinal tract which elicit pharmacodynamic changes. This novel conclusion supports the body of evidence, which advocates the further clinical development of curcumin as a colorectal cancer chemopreventive agent. The lack of quantifiable curcumin in the plasma observed here, even after a dose as high as 3,600 mg is consistent with recent clinical reports, in which oral doses of 30 to 180 mg curcumin failed to establish detectable plasma levels (24), and doses of 4,000 to 12,000 mg yielded curcumin peak levels of only ~ 0.5 to $2 \mu\text{mol/L}$ within 1 hour of administration (25). Furthermore, in a recent clinical phase I study doses up to 3,600 mg curcumin were well tolerated and furnished only trace amounts of parent compound in the blood, but measurable concentrations of curcumin in the feces

and of parent compound plus conjugate metabolites in the urine (26). Another conclusion of the work presented here is that products of metabolic curcumin conjugation are present in the colorectum of humans who have ingested curcumin, but that quantitatively these metabolites contribute only to a very minor extent to the overall colorectal load of curcumin-derived species. This finding is consistent with the notion that pharmacologic effects of curcumin exerted in the colorectum are likely to be caused by the parent compound and not by its metabolites.




Figure 3. Western blot analysis using a monoclonal antibody against COX-2 of (A) normal and (B) malignant colorectal tissue in four patients, who received 3,600 mg curcumin for a week prior to surgery. Lane allocation is as follows: two adjacent lanes per each patient (1 plus 2, 3 plus 4, 5 plus 6, and 7 plus 8); lanes 1, 3, 5, and 7, presurgery biopsies; lanes 2, 4, 6, and 8, tissue samples obtained postcurcumin administration; lane 9, authentic COX-2 protein. C. Blots obtained with a β -tubulin antibody on reblotting of the membrane shown in B. Arrow, molecular weight of COX-2. For details of surgery, sample preparation, and Western blotting, see Materials and Methods.

In a recent study in *Apc^{Min+}* mice, levels of curcumin in the intestinal mucosa were compared with its ability to decrease adenoma formation (7), down-regulate intestinal COX-2 expression and decrease the level of the M₁G adduct in murine intestinal tissue². The results intimate that curcumin doses which result in intestinal mucosal levels in the 100 nmol/g range, are required to reduce the adenoma burden in mice, and that chemopreventive efficacy is reflected by significant decreases in murine adenomatous COX-2 expression and M₁G levels. The data described in the results presented above allow extrapolation of these insights to humans. The curcumin levels observed in the human colorectum after consumption of daily doses of 1,800 or 3,600 mg as described here are of an order of magnitude which has been shown to elicit pharmacologic activity in cells *in vitro* (12, 16-18), although they are only about a tenth of the levels which have been associated with retardation of adenoma formation in the *Apc^{Min+}* mouse model (7). Nevertheless, the antioxidative changes in malignant colorectal tissue, as adjudged by M₁G levels in humans who ingested 3,600 mg curcumin, seem to be quantitatively similar to the extent of reduction of M₁G levels which accompanied the chemopreventive efficacy of curcumin at 0.2% in the diet (equivalent to 300 mg/kg per day) in *Apc^{Min+}* mice. The apparent antioxidative equivalence for curcumin in the intestinal tract between *Apc^{Min+}* mice and humans as reflected by M₁G levels is not surprising in the light of the fact that the curcumin dose in humans equivalent to the 0.2 % dietary concentration used in mice, when calculated on the basis of equivalent body surface area (900 mg/m²), would be 1.6 g per person daily, assuming a body surface area of 1.8 m² accompanying a body weight of 70 kg (26), a dose similar to that shown to be efficacious here. Whilst ingestion of curcumin for a week affected M₁G levels in patients' colorectal tissue, it was insufficient to decrease COX-2 protein expression in this tissue. This result contrasts with the observation in *Apc^{Min+}* mice, in which curcumin consumption, albeit for the postweaning lifetime, drastically reduced COX-2 levels. This reduction may have been the corollary of curcumin-induced retardation of adenoma development. It remains to be established whether ingestion for a term longer than a week would reduce COX-2 protein expression in humans.

Taken together, the results presented here and elsewhere suggest that whilst orally ingested curcumin has low systemic availability, it furnishes sufficient levels in the human intestinal tract to cause pharmacodynamic changes commensurate with intestinal chemoprevention. The low systemic availability of curcumin might be considered a disadvantage because it precludes the use of curcumin as a chemopreventive agent for target organs distant from the gastrointestinal tract. In accordance with this notion, a very recent study suggests that consumption of curcumin by patients at the doses described here results in levels of the agent in normal and malignant liver tissue, which are insufficient to exert pharmacologic activity (27). In contrast, the concentrations of curcumin achieved in the colorectal mucosa as outlined above are consistent with levels needed to exert chemopreventive activity. The "negative targeting" of curcumin (i.e., its lack of ability to reach sites removed from the *loci* of its absorption and excretion) could be a considerable advantage, minimizing potentially detrimental exposure of other organs. All of this evidence suggests that the further evaluation of curcumin as a colorectal cancer chemopreventive agent may be propitious. The results described here in concert with a previous study (27) suggest that a daily dose of 3,600 g is safe in humans. This dose has been shown here to furnish agent levels in the target organ,




Figure 4. M₁G adduct levels in malignant colorectal tissue obtained from patients before (*closed column*) or after (*open column*) administration of curcumin at 450, 1,800, or 3,600 mg/d for a week. *Columns*, mean ($n = 4$ for each dose); *bars*, \pm SD. *, $P < 0.05$. For details of surgery, sample preparation, and M₁G analysis, see Materials and Methods.

which may be adequate to elicit antioxidative changes commensurate with long-term benefit. All of this data is buttressed by extensive mechanistic information on curcumin (28). Thus, the preliminary findings presented here provide some rationale to consider progression of curcumin into phase II evaluation as a cancer chemopreventive agent in patients at risk of colorectal cancer, such as those with familial adenomatous polyposis.

Acknowledgments

We thank J.R Kalba and M. Sysler (Sabinsa Co., Piscataway, NJ) for the generous provision of Sabinsa Curcuminoid C3 capsules; Dr. Cathy Richards, John Jameson, and Adam Scott (Glenfield Hospital, Leicester, United Kingdom) for their involvement in the collection of colorectal tissue specimens; Dr. Lawrence Marnett (Vanderbilt University, TN) for supplying primary anti-M₁G antibody; and Dr. Raj Singh for the supply of M₁G standard.

References

- Omenn GS. Chemoprevention of lung cancer: the rise and demise of β -carotene. *Annu Rev Public Health* 1998;19:73-99.
- Kelloff JS, Crowell JA, Hawk ET, et al. Strategy and planning for chemopreventive drug development: clinical development plans II. *J Cell Biochem* 1994;26S:54-71.
- Ireson CR, Orr S, Jones DL, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in rat plasma and evaluation of their ability to inhibit cyclooxygenase-2 expression. *Cancer Res* 2001;61:1058-64.
- Ireson CR, Jones DJL, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. *Cancer Epidemiol Biomarkers Prev* 2002;11:97-104.
- Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. *Cancer Res* 1995;55:259-66.
- Mahmoud NN, Carothers AM, Grunberger D, et al. Plant phenolics decrease intestinal tumours in an animal model of familial adenomatous polyposis. *Carcinogenesis* 2000;21:921-7.
- Perkins S, Verschoyle RD, Hill KA, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the *Min/+* mouse, a model of familial adenomatous polyposis. *Cancer Epidemiol Biomarkers Prev* 2002;11:535-40.
- Jacoby RF, Seibert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the *min* mouse model of adenomatous polyposis. *Cancer Res* 2000;60:5040-4.
- Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 2000;342:1946-52.

³ Perkins et al., unpublished data.

10. Sharma RA, Ireson CR, Verschoyle RD, et al. Effects of dietary curcumin on glutathione S-transferase and malondialdehyde DNA adducts in rat liver and colon mucosa: relationship with drug levels. *Clin Cancer Res* 2000;7:1452–8.
11. Huang MT, Lysz T, Ferraro T, et al. Inhibitory effect of curcumin on *in vitro* lipoxygenase and cyclooxygenase activities in mouse epidermis. *Cancer Res* 1991;51:813–9.
12. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclooxygenase-2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF- κ B activation via the NIK/IKK signalling complex. *Oncogene* 1999;18:6013–20.
13. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. *Proc Natl Acad Sci U S A* 1994;94:336–40.
14. Kargman SL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthetase-1 and -2 protein in human colon cancer. *Cancer Res* 1995;55:2556–9.
15. Oshima N, Dinchunk JE, Karman SI, et al. Suppression of intestinal polyposis in APC δ 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). *Cell* 1996;87:803–9.
16. Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and anti-tumour promoter induces apoptosis in human leukaemia cells. *Biochim Biophys Acta* 1996;1317:965–1000.
17. Kawamori T, Lubet R, Steele VE, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of cancer. *Cancer Res* 1999;59:597–601.
18. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an *in vivo* inhibitor of angiogenesis. *Mol Med* 1998;4:376–83.
19. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. *Clin Cancer Res* 2001;7:3971–6.
20. Leuratti C, Singh R, Lagneau C, et al. Determination of malondialdehyde-induced DNA damage in human tissues using an immunoslot blot assay. *Carcinogenesis* 1998;19:919–24.
21. Dimberg JA, Samuelsson A, Hugander A, et al. Differential expression of cyclooxygenase 2 in human colorectal cancer. *Gut* 1999;45:730–2.
22. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. *JAMA* 1999;282:1254–7.
23. Wiese FW, Thompson PA, Warneke J, et al. Variation in cyclooxygenase expression levels within the colorectum. *Mol Carcinog* 2003;37:25–31.
24. Sharma RA, McLelland HR, Ireson CR, et al. Pharmacodynamic and pharmacokinetic study of oral *Curcuma* extract in patients with colorectal cancer. *Clin Cancer Res* 2001;7:1894–900.
25. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. *Anticancer Res* 2001;21:2895–900.
26. Freireich EJ, Gehan EA, Rall DP, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. *Cancer Chemother Rep* 1966;50:219–44.
27. Garcea G, Jones DJL, Dennison AR, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. *Br J Cancer* 2004;90:1011–5.
28. Gescher A, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: a salutary tale of failure and promise. *Lancet Oncol* 2001;2:371–9.